Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Submitted by amarin on Wed, 02/19/2025 - 13:30
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and full year 2024 results followed

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Submitted by amarin on Mon, 12/16/2024 - 12:00
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe -- -- European

Amarin Appoints Peter Fishman Chief Financial Officer

Submitted by amarin on Fri, 12/13/2024 - 14:00
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the